CN115364085A - Composite tablet for relieving premature ejaculation - Google Patents
Composite tablet for relieving premature ejaculation Download PDFInfo
- Publication number
- CN115364085A CN115364085A CN202210930145.6A CN202210930145A CN115364085A CN 115364085 A CN115364085 A CN 115364085A CN 202210930145 A CN202210930145 A CN 202210930145A CN 115364085 A CN115364085 A CN 115364085A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- premature ejaculation
- theanine
- relieving
- gamma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010036596 premature ejaculation Diseases 0.000 title claims abstract description 42
- 239000002131 composite material Substances 0.000 title claims description 7
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims abstract description 84
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 78
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 39
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 39
- 229940026510 theanine Drugs 0.000 claims abstract description 38
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 241001122767 Theaceae Species 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims description 24
- 238000011282 treatment Methods 0.000 claims description 24
- 229940088594 vitamin Drugs 0.000 claims description 23
- 229930003231 vitamin Natural products 0.000 claims description 23
- 235000013343 vitamin Nutrition 0.000 claims description 23
- 239000011782 vitamin Substances 0.000 claims description 23
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 16
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 16
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 14
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 14
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 13
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 claims description 8
- SERLAGPUMNYUCK-YJOKQAJESA-N 6-O-alpha-D-glucopyranosyl-D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-YJOKQAJESA-N 0.000 claims description 8
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 8
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 8
- 239000004376 Sucralose Substances 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 229960003512 nicotinic acid Drugs 0.000 claims description 8
- 235000001968 nicotinic acid Nutrition 0.000 claims description 8
- 239000011664 nicotinic acid Substances 0.000 claims description 8
- 229940055726 pantothenic acid Drugs 0.000 claims description 8
- 235000019161 pantothenic acid Nutrition 0.000 claims description 8
- 239000011713 pantothenic acid Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 8
- 235000019408 sucralose Nutrition 0.000 claims description 8
- 229960003080 taurine Drugs 0.000 claims description 8
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 8
- 235000008939 whole milk Nutrition 0.000 claims description 8
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 7
- 229960002685 biotin Drugs 0.000 claims description 7
- 235000020958 biotin Nutrition 0.000 claims description 7
- 239000011616 biotin Substances 0.000 claims description 7
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims description 7
- 229960000304 folic acid Drugs 0.000 claims description 7
- 235000019152 folic acid Nutrition 0.000 claims description 7
- 239000011724 folic acid Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 239000000905 isomalt Substances 0.000 claims description 5
- 235000010439 isomalt Nutrition 0.000 claims description 5
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 229930003316 Vitamin D Natural products 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000019166 vitamin D Nutrition 0.000 claims description 2
- 239000011710 vitamin D Substances 0.000 claims description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- 229940046008 vitamin d Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 10
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 11
- -1 compound vitamin Chemical class 0.000 description 5
- 230000001568 sexual effect Effects 0.000 description 5
- DATAGRPVKZEWHA-UHFFFAOYSA-N L-gamma-glutamyl-n-ethylamine Natural products CCNC(=O)CCC(N)C(O)=O DATAGRPVKZEWHA-UHFFFAOYSA-N 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 206010001497 Agitation Diseases 0.000 description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 229920001609 Poly(3,4-ethylenedioxythiophene) Polymers 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
- 210000003899 penis Anatomy 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- 208000021473 Ejaculation disease Diseases 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Gynecology & Obstetrics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a combined tablet for relieving premature ejaculation, which comprises a composition for relieving premature ejaculation and pharmaceutically available auxiliary materials. A composition for the relief of premature ejaculation comprising gamma-aminobutyric acid and theanine; the mass ratio of the gamma-aminobutyric acid to the theanine in the tea leaves is 1. The invention combines the gamma-aminobutyric acid and the tea theanine, and the mixture is mixed with the auxiliary materials to prepare the tablet, which can obviously relieve premature ejaculation, has synergistic effect and no toxic or side effect.
Description
Technical Field
The invention relates to the technical field of medical medicines or health-care foods, in particular to a combined tablet for relieving premature ejaculation.
Background
Premature ejaculation is a common sexual dysfunction disease of males and belongs to ejaculation disorder. Ejaculation is a reflex regulated by the central nervous system of the brain, so premature ejaculation is mostly caused by the weakening of the inhibitory process of the cerebral cortex, hyperexcitability of the higher central nervous system, weakening of the inhibitory process of the primary ejaculation central system of the spinal cord and hyperexcitability of the sacral medulla ejaculation central system. At present, premature ejaculation treatment mainly takes antidepressant drug treatment as main treatment, and although the curative effect is exact, the side effect is large and the recurrence rate is high. Therefore, there is a need to find other relatively effective and safe therapeutic approaches.
Gamma-aminobutyric acid (GABA) is a main inhibitory neurotransmitter in the central nervous system of mammals, mediates over 40 percent of inhibitory nerve conduction, and has the main physiological functions of reducing blood pressure, promoting sleep, enhancing memory, resisting anxiety, preventing and treating epilepsy, influencing brain aging, regulating male reproductive function, detoxifying and the like.
Evidence from human electroencephalographic (EEG) studies indicates that L-theanine has a direct effect on the brain, significantly increasing activity in the alpha band, suggesting that it may relax psychotropic without causing lethargy. L-theanine can prevent L-glutamic acid from binding with brain glutamate receptor, and oral administration of L-theanine can inhibit cortical neuron excitation to exert anti-stress effect. L-theanine not only can reduce anxiety, but also can relieve the blood pressure rise of high-stress response adults, is clinically used for Chronic Fatigue Syndrome (CFS), relieves fatigue after exercise, and relaxes and improves the emotion and cognitive level.
According to the current reports, the gamma-aminobutyric acid and the theanine in the tea leaves are not used for treating premature ejaculation.
Disclosure of Invention
The invention aims to provide a composition for relieving premature ejaculation, and aims to solve the problems of great side effect and high recurrence rate of the current medicament for treating premature ejaculation. The invention discovers that theanine can also relieve premature ejaculation, and the gamma-aminobutyric acid can be cooperated with the theanine to realize synergistic interaction.
To achieve the above objects, the present invention first provides a composition for relieving premature ejaculation, comprising gamma-aminobutyric acid and theanine; the mass ratio of the gamma-aminobutyric acid to the theanine in the tea leaves is 1.
In a preferable embodiment of the invention, the mass ratio of the gamma-aminobutyric acid to the theanine in the tea leaves is 1:2-2:1.
As a preferable scheme of the invention, the gamma-aminobutyric acid is food-grade or pharmaceutical-grade raw material.
As a preferable scheme of the invention, the theanine is a food-grade or pharmaceutical-grade raw material.
The invention also provides application of the composition in preparing a medicament for treating premature ejaculation.
The invention also provides a combined tablet for relieving premature ejaculation, which comprises the composition for relieving premature ejaculation and pharmaceutically acceptable auxiliary materials.
The invention also provides a preparation method of the combined tablet, which comprises the following steps:
step 1: uniformly mixing the gamma-aminobutyric acid, the theanine and auxiliary materials according to the formula ratio for later use;
and 2, step: tabletting the mixed materials to obtain tablets.
The invention also provides a composite tablet for relieving premature ejaculation, which comprises the following raw materials in percentage by weight: 5 to 25 percent of gamma-aminobutyric acid, 5 to 25 percent of theanine, 3 to 20 percent of taurine, 0.1 to 8 percent of multivitamin, 10 to 40 percent of isomaltitol, 10 to 40 percent of whole milk powder, 0.3 to 1.5 percent of magnesium stearate and 0.01 to 0.05 percent of sucralose.
The compound vitamin comprises the following components in daily dosage of the combined tablet: 0-3000 mug of vitamin A, 0-50 mug of vitamin D, 0-700 mg of alpha-TE of vitamin E and vitamin B 1 0.2-4 mg and vitamin B 2 0.2-2 mg of vitamin B 6 0.2-60 mg and vitamin B 12 0-4 mug of vitamin C15-2000 mg. 0-1000 mug of folic acid, 0-50 mug of biotin, 2.1-35 mg of nicotinic acid and 0.8-7 mg of pantothenic acid.
According to the preferred embodiment of the invention, the raw materials for preparing the combined tablet for relieving premature ejaculation comprise the following components in percentage by weight: 16% of gamma-aminobutyric acid, 13% of theanine, 20% of taurine, 6.67% of vitamin complex, 25% of isomaltitol, 18.30% of whole milk powder, 1% of magnesium stearate and 0.03% of sucralose.
According to a preferred embodiment of the present invention, the multivitamins comprise the following components in terms of daily dosage of the combined tablet: vitamin B 1 2.00mg of vitamin B 2 1.10mg, vitamin B 6 1.10mg, vitamin B 12 1.20 mug, vitamin C60 mg, folic acid 120 mug, biotin 5 mug, nicotinic acid 15mg and pantothenic acid 4.20mg.
As a preferable scheme of the invention, the combined sheet is one or more of an oblong shape, a circular shape, a triangular shape and a heart shape.
Compared with the prior art, the invention has the beneficial effects that:
the invention combines the gamma-aminobutyric acid and the tea theanine, is used for relieving the premature ejaculation symptom, has the characteristics of good effect, less toxic and side effects and the like, and has good practicability.
Detailed Description
The invention is further described below with reference to specific examples, with the advantages and features of the invention being clearer as the examples follow. These examples are merely illustrative and do not set any limit to the scope of the invention. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention, and that such changes and modifications may be made without departing from the spirit and scope of the invention.
Example 1 GABA + tea theanine formulation:
the composition tablet for relieving premature ejaculation comprises the following raw materials in percentage by weight:
| name of raw materials | The dosage is% |
| Gamma-aminobutyric acid | 16.00 |
| Theanine | 13.00 |
| Taurine | 20.00 |
| Compound vitamin | 6.67 |
| Isomalt | 25.00 |
| Whole milk powder | 18.30 |
| Magnesium stearate | 1.00 |
| Sucralose | 0.03 |
| In total | 100.00 |
The gamma-aminobutyric acid is a food-grade or pharmaceutical-grade raw material. The theanine is a food-grade or pharmaceutical-grade raw material.
The vitamin complex comprises the following components (content per day, namely, the same as the following on the basis of daily dosage): vitamin B 1 2.00mg of vitamin B 2 1.10mg, vitamin B 6 1.10mg, vitamin B 12 1.20 mug, vitamin C60 mg, folic acid 120 mug, biotin 5 mug, nicotinic acid 15mg and pantothenic acid 4.20mg.
The method for preparing the composite tablet of example 1 includes the following steps:
step 1: uniformly mixing the raw materials for later use;
and 2, step: the mixed materials are tabletted into tablets, and the weight of the tablets is 1.5g.
The tablets obtained in the step 2 are round tablets.
Example 2 GABA + tea theanine formulation:
the composition tablet for relieving premature ejaculation comprises the following raw materials in percentage by weight:
| name of raw materials | The dosage is% |
| Gamma-aminobutyric acid | 20.00 |
| Theanine | 10.00 |
| Taurine | 10.00 |
| Compound vitamin | 5.49 |
| Isomalt | 30.00 |
| Whole milk powder | 23.50 |
| Magnesium stearate | 1.00 |
| Sucralose | 0.01 |
| Total of | 100.00 |
The gamma-aminobutyric acid is a food-grade or pharmaceutical-grade raw material. The theanine is a food-grade or pharmaceutical-grade raw material.
The vitamin complex comprises the following components (content per day): vitamin B 1 2.00mg of vitamin B 2 1.10mg, vitamin B 6 1.10mg, vitamin C60 mg, nicotinic acid 15mg, pantothenic acid 4.20mg.
The method for preparing the composite tablet of example 2 comprises the following steps:
step 1: uniformly mixing the raw materials for later use;
step 2: the mixed materials are tabletted into tablets, and the weight of the tablets is 1.5g.
The tablets obtained in the step 2 are round tablets.
Example 3 GABA + tea theanine formulation:
the composition tablet for relieving premature ejaculation comprises the following raw materials in percentage by weight:
the gamma-aminobutyric acid is a food-grade or pharmaceutical-grade raw material. The theanine is a food-grade or pharmaceutical-grade raw material.
The vitamin complex comprises the following components (content per day): vitamin A200 μ g, vitamin D2.0 μ g, vitamin E10.0 mg alpha-TE, vitamin B 1 2.00mg of vitamin B 2 1.10mg, vitamin B 6 1.10mg, vitamin B 12 1.20 mug, vitamin C60 mg, folic acid 120 mug, biotin 5 mug, nicotinic acid 15mg and pantothenic acid 4.20mg.
Example 3 a method of making a combined tablet includes the steps of:
step 1: uniformly mixing the raw materials for later use;
and 2, step: the mixed materials are tabletted to form tablets, and the weight of each tablet is 1.5g.
The tablets obtained in the step 2 are round tablets.
Comparative example 4 GABA-only formulation
Tablets were prepared according to the preparation method of example 1, but the formulation did not contain theanine, and the specific formulation was as follows:
| name of raw materials | The dosage is% |
| Gamma-aminobutyric acid | 29.00 |
| Taurine | 20.00 |
| Compound vitamin | 6.67 |
| Isomalt | 25.00 |
| Whole milk powder | 18.30 |
| Magnesium stearate | 1.00 |
| Sucralose | 0.03 |
| Total of | 100.00 |
The vitamin complex comprises the following components (content per day): vitamin B 1 2.00mg of vitamin B 2 1.10mg, vitamin B 6 1.10mg, vitamin B 12 1.20 mug, vitamin C60 mg, folic acid 120 mug, biotin 5 mug, nicotinic acid 15mg and pantothenic acid 4.20mg.
Comparative example 5 formulation containing theanine alone
Tablets were prepared according to the preparation method of example 1, but the formulation did not contain GABA and the specific formulation was as follows:
| name of raw materials | The dosage is% |
| Theanine from tea | 29.00 |
| Taurine | 20.00 |
| Compound vitamin | 6.67 |
| Isomalt | 25.00 |
| Whole milk powder | 18.30 |
| Magnesium stearate | 1.00 |
| Sucralose | 0.03 |
| Total of | 100.00 |
The vitamin complex comprises the following components (content per day): vitamin B 1 2.00mg of vitamin B 2 1.10mg, vitamin B 6 1.10mg, vitamin B 12 1.20 mug, 60mg of vitamin C, 120 mug of folic acid, 5 mug of biotin, 15mg of nicotinic acid and 4.20mg of pantothenic acid.
Examples of clinical experiments
The present invention will be further described below by way of statistics of the effect of premature ejaculation treatment in patients in examples and comparative examples. The counted number of patients is 30 in total, and the members in the group meet the following conditions:
male, 18-60 years old;
the PEDT score is more than or equal to 11 points. The patient scores according to a PEDT premature ejaculation diagnosis table, and if the score is more than or equal to 11, the premature ejaculation problem is shown; score 9-10, indicating possible premature ejaculation; the score is less than or equal to 8 points, which shows that the premature ejaculation problem does not exist;
the average ejaculation latency time of the patient is less than 3 minutes;
premature ejaculation occurred for at least 2 months prior to treatment;
a healthy person with no history of disease or any physical examination abnormalities, laboratory examination abnormalities, imaging examination abnormalities, and electrocardiographic examination abnormalities;
during the treatment period, the patient stops other types of conventional treatments, such as medications, behavioral treatments, or topical treatments.
Typical case 1
Chen is old, male, 43 years old. The patient is married for more than 9 years, adheres to physical exercise for a long time, is healthy, has normal sexual life when just married, has good penis erection, has the average latency time of ejaculation of about 10 minutes each time, and has strong ejaculation control capability; the history of special diseases is avoided, and the history of prostatitis and urethritis is denied; the child is born and healthy. In recent years, as work is busy and much remuneration is caused, physical exercise is reduced, fatigue, anxiety and irregular life appear, premature ejaculation occurs although the male can erect normally, the latency time of ejaculation every time is shortened to about 2 minutes, the ejaculation control capability is obviously reduced, and the sexual satisfaction of couples and partners is seriously influenced.
Typical case 2
Zhangqi, male, 25 years old, unmarried, university graduate for 3 years, rarely attend sports at ordinary times, like to chase after all night, play games, just talk about female friends, describe oneself easy to excite, penis erection is good, but ejaculation control ability is poor, average ejaculation latency time is less than 1 minute each time; the health is stated by oneself, no special disease history exists, but the pregnancy is worried about, and in addition, the lack of sexual experience and certain mental stress exist, and the time is short, so the sexual satisfaction of both parties is seriously influenced.
Treatment group 1 used the formulation of example 1 and treatment groups 2 and 3 used the formulations of comparative examples 4 and 5, respectively.
The treatment scheme comprises the following steps: the medicine is taken continuously for 5 days in asexual life, 1 tablet per day, the treatment group 1 is equivalent to taking 240mg of GABA and 195mg of theanine per day, the treatment group 2 is equivalent to taking 435mg of GABA per day, and the treatment group 3 is equivalent to taking 435mg of theanine per day; the sexual life day is half an hour ahead of the day, 2 tablets are taken, the treatment group 1 is equivalent to taking 480mg of GABA and 390mg of theanine, the treatment group 2 is equivalent to taking 870mg of GABA, and the treatment group 3 is equivalent to taking 870mg of theanine.
The treatment effect statistics are as follows:
it can be seen that the treatment group 1 (GABA + theanine), the treatment group 2 (only GABA) and the treatment group 3 (only theanine) all can relieve premature ejaculation, but the treatment group 1 is significantly better than the two alone, which indicates that the combination of the two can achieve synergistic effect.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is specific and detailed, but not to be understood as limiting the scope of the present invention. It will be apparent to those skilled in the art that various changes and modifications can be made without departing from the spirit and scope of the invention.
Claims (10)
1. A composition for the relief of premature ejaculation, comprising: comprises gamma-aminobutyric acid and theanine; the mass ratio of the gamma-aminobutyric acid to the theanine in the tea leaves is 1.
2. The composition for relieving premature ejaculation according to claim 1, wherein: the mass ratio of the gamma-aminobutyric acid to the theanine in the tea leaves is 1:2-2:1.
3. The composition for relieving premature ejaculation according to claim 1, wherein: the gamma-aminobutyric acid is a food-grade or pharmaceutical-grade raw material.
4. The composition for relieving premature ejaculation according to claim 1, wherein: the theanine is a food-grade or pharmaceutical-grade raw material.
5. Use of a composition according to any one of claims 1 to 4 in the manufacture of a medicament for the treatment of premature ejaculation.
6. A combination tablet for relieving premature ejaculation, which comprises the composition for relieving premature ejaculation according to any one of claims 1 to 4 and pharmaceutically acceptable auxiliary materials.
7. A method for preparing the composite sheet of claim 6, comprising the steps of:
step 1: uniformly mixing the gamma-aminobutyric acid, the theanine and auxiliary materials according to the formula ratio for later use;
step 2: tabletting the mixed materials to obtain tablets.
8. The composite tablet for relieving premature ejaculation is characterized by comprising the following raw materials in percentage by weight: 0.5 to 25 percent of gamma-aminobutyric acid, 0.5 to 25 percent of theanine, 3 to 20 percent of taurine, 0.1 to 8 percent of vitamin complex, 10 to 40 percent of isomaltitol, 10 to 40 percent of whole milk powder, 0.3 to 1.5 percent of magnesium stearate and 0.01 to 0.05 percent of sucralose.
9. The combination tablet for relieving premature ejaculation according to claim 8, wherein the vitamin complex comprises the following components in terms of daily dosage: 0-3000 mug of vitamin A, 0-50 mug of vitamin D, 0-700 mg of alpha-TE of vitamin E and vitamin B 1 0.2-4 mg and vitamin B 2 0.2-2 mg of vitamin B 6 0.2-60 mg and vitamin B 12 0 to 4 mu g, 15 to 2000mg of vitamin C, 0 to 1000 mu g of folic acid, 0 to 50 mu g of biotin, 2.1 to 35mg of nicotinic acid and 0.8 to 7mg of pantothenic acid.
10. The composition tablet for relieving premature ejaculation according to claim 8, wherein the composition tablet is prepared from the following raw materials in percentage by weight: 16% of gamma-aminobutyric acid, 13% of theanine, 20% of taurine, 6.67% of vitamin complex, 25% of isomalt, 18.30% of whole milk powder, 1% of magnesium stearate and 0.03% of sucralose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210930145.6A CN115364085A (en) | 2022-08-03 | 2022-08-03 | Composite tablet for relieving premature ejaculation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210930145.6A CN115364085A (en) | 2022-08-03 | 2022-08-03 | Composite tablet for relieving premature ejaculation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115364085A true CN115364085A (en) | 2022-11-22 |
Family
ID=84064682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210930145.6A Withdrawn CN115364085A (en) | 2022-08-03 | 2022-08-03 | Composite tablet for relieving premature ejaculation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115364085A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104366510A (en) * | 2014-11-28 | 2015-02-25 | 北京康比特体育科技股份有限公司 | Tea leaf theanine health-care food composition and preparation method thereof |
-
2022
- 2022-08-03 CN CN202210930145.6A patent/CN115364085A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104366510A (en) * | 2014-11-28 | 2015-02-25 | 北京康比特体育科技股份有限公司 | Tea leaf theanine health-care food composition and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 谢英彪等, 同济大学出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10369182B2 (en) | Compositions and methods for treating insomnia and other sleep related disorders | |
| US6335021B1 (en) | Composition for controlling mood disorders in healthy individuals | |
| US6582735B2 (en) | Compositions and methods of use for extracts of magnoliaceae plants | |
| AU2005249860B2 (en) | Therapy for multiple sclerosis | |
| EP4255402A1 (en) | Cannabidiol for the treatment of refractory seizures | |
| US11744833B2 (en) | Pharmaceutical compositions and methods for treatment of insomnia | |
| HOEFER et al. | Myasthenia gravis and epilepsy | |
| US20230145635A1 (en) | Treatment of menstrual cycle-induced symptoms | |
| US20040162245A1 (en) | Use of ribose to treat fibromyalgia | |
| CN115364085A (en) | Composite tablet for relieving premature ejaculation | |
| CN108451951A (en) | A kind of new drug for treating neurogenic disease | |
| CN116829135A (en) | Treatment of sleep apnea with cannabidiol | |
| WO2022017911A1 (en) | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to brain injury | |
| CN105616581A (en) | Glipizide-containing pharmaceutical composition for treating diabetes and preparation method thereof | |
| EP2727595B1 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
| CN112641765B (en) | Anti-fatigue pharmaceutical application of propofol | |
| EP1095658A2 (en) | Use of ribose to treat fibromyalgia | |
| MX2015003879A (en) | Methods for alleviating symptoms of multiple sclerosis based on apoaequorin-containing compositions. | |
| KR101351978B1 (en) | Pharmaceutical and food compositions for preventing or treating arthritis comprising crush of tuna eyeball as active ingredients | |
| EP4193992A1 (en) | New composition and uses thereof | |
| Sapeika | Drugs in obesity | |
| WO2023200906A1 (en) | Treatment of seizure disorders | |
| EP1514545B1 (en) | Use of tolperisone for the treatment of spasms of organes consisting essentially of smooth muscles. | |
| KR20240055438A (en) | Composition for lipolysis with improved lipolysis effect and injection formulation comprising same | |
| CN117180353A (en) | A Chinese medicinal composition for treating diabetes, and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20221122 |